NCT00857350

The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 60 (actual)
• Sponsor: Yale University · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

HIV drug resistance presents a significant public heath problem. This proposal is designed to explore the association between ongoing illicit drug use and the prevalence of HIV drug resistance among HIV+ opioid dependent patients receiving opioid agonist treatment with the following hypotheses: 1. Hypothesis 1: The prevalence of HIV drug resistance will range between 10% and 30%. 2. Hypothesis 2: Patients with evidence of ongoing illicit drug use will be more likely to have HIV drug resistance.

Conditions

• HIV Positive
• Opioid Dependence
• Opioid Agonist Treatment
• HIV Infections

Timeline

• Start date: 2008-06-01
• Primary completion: 2010-06-01
• Completion: 2012-09-01
• First posted: 2009-03-06
• Last updated: 2013-07-22

Locations

1 site across 1 country: United States